Metformin (PCOS) vs Vaniqa (Eflornithine): Which One Actually Treats Your PCOS?

The Core Difference: Systemic vs Local

Metformin ER and Vaniqa are not competitors in any clinical sense. Metformin ER is an oral biguanide that lowers hepatic glucose output and improves insulin sensitivity across multiple organ systems. Vaniqa is a topical enzyme inhibitor that slows the rate of facial hair growth by blocking ornithine decarboxylase inside the hair follicle. They work at completely different sites, through completely different mechanisms, to address completely different problems.

If your main concern is excess facial hair from PCOS, you may need both, not one instead of the other.

Why PCOS Produces Facial Hair in the First Place

PCOS causes elevated androgens, primarily testosterone and androstenedione, which bind to androgen receptors in hair follicles and convert vellus hair to terminal (coarse, dark) hair. Insulin resistance, present in roughly 70% of women with PCOS, amplifies this by stimulating ovarian androgen production and suppressing sex-hormone-binding globulin (SHBG). Lower SHBG means more free testosterone available to act on your skin.

Metformin addresses this chain at the insulin-resistance step. Vaniqa addresses the follicle itself, downstream of all of that hormonal signaling.

What "Efficacy" Means Depends on the Outcome

When someone asks which drug is more effective, the answer depends entirely on what you are measuring.

• Menstrual cycle regularity: Metformin wins. Vaniqa has no effect.
• Ovulation rate: Metformin wins. Vaniqa has no effect.
• Fasting insulin and HOMA-IR: Metformin wins. Vaniqa has no effect.
• Rate of facial hair growth: Vaniqa wins. Metformin has modest, inconsistent effects on hirsutism scores.
• Acne: Metformin may help modestly. Vaniqa has no effect on acne.

There is no published randomized controlled trial directly comparing metformin ER with eflornithine 13.9% cream for any shared PCOS outcome.

What the Evidence Actually Shows for Each Drug

Metformin ER in PCOS: The Cochrane Picture

The 2019 Cochrane systematic review of metformin in PCOS, covering 48 randomized trials and over 4,000 women, found that metformin improves ovulation rates and menstrual frequency compared to placebo. The review also found metformin likely reduces fasting insulin, androgen levels, and body weight modestly, though effect sizes vary widely by population and dose.

The review does not support metformin as a primary hair-removal strategy. Ferriman-Gallwey hirsutism scores, which quantify body and facial hair distribution, did improve in some metformin arms, but the evidence was rated low to moderate quality, and the effect size was small compared to oral contraceptives or anti-androgens like spironolactone.

Dose and Formulation

Extended-release metformin (metformin ER) is preferred over immediate-release in clinical practice because the ER formulation produces significantly fewer gastrointestinal side effects, which are the most common reason women stop taking it. Typical starting dose is 500 mg once daily with the evening meal, titrated over 4-8 weeks to 1,500-2,000 mg daily depending on tolerance and glycemic response.

How Long Before You See Results

Cycle regularity in PCOS typically improves within 3-6 months on metformin. Androgen levels may take 6 months to shift meaningfully. If you have not had a period within 6 months of starting at therapeutic dose, that is a signal to reassess whether metformin alone is sufficient for your goals.

Eflornithine 13.9% Cream (Vaniqa): The Facial Hair Data

The landmark key RCT of eflornithine 13.9% cream, published in 2000, enrolled 594 women with unwanted facial hair and randomized them to twice-daily eflornithine or vehicle cream for 24 weeks. At week 24, 58% of eflornithine users showed improvement in facial hair growth compared with 34% of vehicle users, a statistically significant difference. The drug does not remove hair. It slows the rate of new growth, so your existing hair-removal routine, whether shaving, threading, waxing, or laser, needs to continue alongside it.

What Eflornithine Does Not Do

Eflornithine does not reduce androgen levels. It does not regularize your cycle. It does not improve insulin sensitivity. For a woman with PCOS, using Vaniqa without addressing the underlying androgen excess is like putting a slower leak in a bucket that is still overfilling.

How Quickly Does It Work

Most women see a reduction in hair growth rate within 4-8 weeks. If you see no change by 16 weeks of twice-daily application, the prescribing guidance suggests that continued use is unlikely to provide benefit. Hair growth returns to baseline roughly 8 weeks after stopping.

Sex-Specific Physiology: Why Women Respond Differently

Metformin PK in Women vs Men

Women have lower renal tubular secretion of metformin on average, which means slightly higher plasma concentrations at the same weight-based dose compared to men. Women also tend to have more subcutaneous and less visceral fat, which can modify the insulin-sensitizing response. Clinical trials in PCOS use female-only populations, so the Cochrane data is directly applicable to you, unlike many general diabetes trials where women were underrepresented.

Hormonal Cycle Effects on Eflornithine

No published data specifically examines whether eflornithine efficacy varies across the menstrual cycle. Androgen levels do fluctuate across the cycle, with a modest mid-cycle rise around ovulation, but skin application of eflornithine acts locally within the follicle independent of circulating hormone levels, so cycle timing is unlikely to alter efficacy meaningfully.

PCOS Phenotype Matters

PCOS has four recognized phenotypes under the Rotterdam criteria, and not all of them involve insulin resistance at the same degree. Women with the classic phenotype (polycystic ovaries, oligo-anovulation, and clinical or biochemical hyperandrogenism) tend to show the strongest metabolic response to metformin. Women with a lean PCOS phenotype may have less insulin resistance and therefore a smaller metformin response on cycle regularity, though androgen reduction can still occur.

Eflornithine is phenotype-agnostic. It works at the follicle regardless of whether your hirsutism is driven by insulin-amplified androgens or a different mechanism.

Life Stage: Who Gets Which Drug When

Reproductive Years (Not Trying to Conceive)

During the reproductive years when pregnancy is not the goal, the standard first-line PCOS treatment for menstrual irregularity is combined oral contraceptives (COCs), not metformin. Metformin is used as an adjunct or as a standalone option in women who cannot tolerate or do not want hormonal contraception. Eflornithine can be added at any point for facial hair, alongside whatever systemic treatment you are using.

Trying to Conceive (TTC)

Metformin has a meaningful role in the TTC setting. It improves ovulation rates in women with PCOS and may reduce the risk of ovarian hyperstimulation syndrome (OHSS) when used alongside gonadotropins. ASRM guidelines support metformin as an adjunct to clomiphene for ovulation induction in PCOS.

Eflornithine should be stopped before attempting conception given inadequate human safety data (see the pregnancy section below).

Perimenopause

PCOS does not disappear at perimenopause. Androgen levels may actually persist longer in women with PCOS compared to women without it, and insulin resistance can worsen as estrogen declines. Metformin continues to offer metabolic benefit in perimenopausal women with PCOS. Facial hair may also worsen in perimenopause as estrogen declines and the androgen-to-estrogen ratio rises, making eflornithine more relevant, not less, at this life stage.

Postmenopause

Post-menopause, PCOS-associated hyperandrogenism generally improves as ovarian androgen production declines, but some women continue to have persistent hirsutism and insulin resistance. Metformin use in postmenopausal women with PCOS is off-label for the PCOS indication specifically, though it remains standard of care for type 2 diabetes and prediabetes. Eflornithine remains an option for facial hair in postmenopausal women with no contraindications.

Pregnancy, Lactation, and Contraception

This section is required reading if there is any chance you might become pregnant while using either of these drugs.

Metformin in Pregnancy

Metformin is not teratogenic based on current human data. It crosses the placenta. The drug is widely used to manage gestational diabetes mellitus (GDM) and is used off-label in the first trimester in women with PCOS who became pregnant while taking it. ACOG practice guidelines acknowledge metformin as an effective oral agent for GDM, though they note long-term offspring data are still accumulating.

Women with PCOS who are not trying to conceive should use reliable contraception while on metformin if they do not want to become pregnant, because metformin can restore ovulation in previously anovulatory women, meaning pregnancy is now possible when it was not before. This is one of the most commonly missed counseling points in PCOS care.

Metformin is present in breast milk at low levels. The relative infant dose is estimated at approximately 0.28-1% of the maternal weight-adjusted dose, which is considered low. Most lactation specialists and The Menopause Society and ACOG-affiliated guidance consider it compatible with breastfeeding, though a conversation with your provider is appropriate if your infant is preterm or has renal immaturity.

Eflornithine (Vaniqa) in Pregnancy and Lactation

Eflornithine is classified FDA Pregnancy Category C. Animal reproductive studies showed embryotoxicity at systemic doses. The FDA prescribing information states that eflornithine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because the drug is cosmetic in indication, that benefit-risk calculation almost never favors use in pregnancy. Stop Vaniqa before attempting conception.

Excretion into human breast milk is unknown. Given the lack of data, eflornithine should not be used during breastfeeding unless clearly necessary, which is rarely the case for a cosmetic indication.

Contraception requirement: Because eflornithine should be avoided in pregnancy and because metformin can restore ovulation unexpectedly, women with PCOS on either drug who do not want to be pregnant need effective contraception. This is especially true in the first 3-6 months of metformin initiation, when ovulatory function may resume before cycle regularity is obvious.

Who This Is Right For (and Who It Is Not)

Metformin ER Is Likely Right for You If

• You have PCOS with confirmed or suspected insulin resistance (fasting insulin above reference range, elevated HOMA-IR, BMI >25 with central adiposity, or a history of GDM or prediabetes)
• Your menstrual cycles are irregular and you want to address the underlying hormonal cause
• You are trying to conceive and have not yet responded to lifestyle intervention alone
• You cannot or prefer not to use combined oral contraceptives
• You are perimenopausal with worsening insulin resistance on a background of PCOS

Metformin ER Is Less Likely to Be Right for You If

• Your only PCOS symptom is facial hair and your cycles are regular
• Your renal function is impaired (eGFR <30 is a contraindication; caution begins at eGFR <45)
• You have a history of lactic acidosis or conditions that predispose to it
• GI side effects on even the ER formulation are intolerable after an adequate trial

Vaniqa Is Likely Right for You If

• Unwanted facial hair is your primary concern and you want to extend the results of your hair-removal routine
• You are already on systemic PCOS treatment (COCs, spironolactone, metformin) and want additional local control of facial hair
• You are postmenopausal with persistent hirsutism and no other systemic PCOS drivers left to treat

Vaniqa Is Not Right for You If

• You are pregnant or planning to conceive in the near term
• You are breastfeeding
• You expect it to address any PCOS symptom other than the rate of facial hair growth
• You have not yet tried or optimized systemic androgen-lowering treatment

Combining Both: When It Makes Clinical Sense

For many women with PCOS and significant hirsutism, the practical answer is metformin for the systemic hormonal picture and eflornithine for the facial hair in the meantime. Eflornithine is frequently combined with laser hair removal. The eflornithine plus laser RCT demonstrated that combination outperforms laser alone in reducing regrowth, which is directly relevant to PCOS patients who often pursue laser as a long-term solution.

Metformin lowers circulating androgens over months. Eflornithine works at the follicle within weeks. The two timelines are complementary: Vaniqa can manage visible hair while metformin is working upstream on the hormonal environment that drives it.

Side Effects: What Women Report Most

Metformin ER

The most common side effects are gastrointestinal: nausea, loose stools, and a metallic taste. The ER formulation reduces but does not eliminate these. Taking it with the largest meal of the day and titrating slowly (500 mg per week) reduces GI burden substantially. Vitamin B12 depletion occurs with long-term use. Check B12 annually if you have been on metformin for more than 12 months.

Lactic acidosis is rare but serious. Risk rises with renal impairment, dehydration, heavy alcohol use, and IV contrast dye administration. Hold metformin 48 hours before and after iodinated contrast in most protocols.

Eflornithine 13.9% Cream

Local skin reactions are the main issue: stinging, burning, tingling, and redness at the application site, affecting roughly 3-7% of users in trials. Acne at the application site is reported by some women, which is particularly frustrating given that PCOS already raises acne risk. Systemic absorption from topical application is low.

A Framework for Choosing Between Them

Ask yourself three questions in order:

1. Is my primary goal hormonal or cosmetic? If hormonal (cycle, ovulation, insulin, weight), metformin. If purely cosmetic facial hair, eflornithine.
2. Am I or could I become pregnant? If yes or possibly, eflornithine is off the table. Metformin may continue with provider guidance.
3. Have I optimized systemic PCOS treatment first? If not, adding eflornithine before addressing androgen excess is addressing the symptom while ignoring the source.

Women with PCOS and hirsutism who answer "both hormonal and cosmetic" to question one are the population most likely to benefit from a combination approach rather than choosing between these two drugs.

Evidence Gap: What We Do Not Yet Know

Women have been underrepresented in metabolic and dermatologic trials historically. The eflornithine key RCT enrolled women with unwanted facial hair broadly, not PCOS specifically, so efficacy data specific to PCOS-driven hirsutism is extrapolated rather than directly studied. It is plausible that PCOS-driven hirsutism, which involves higher androgen drive than idiopathic hirsutism, may respond differently to eflornithine, but no trial has tested this directly.

The Cochrane metformin review explicitly noted that evidence on hirsutism outcomes was low-to-moderate quality across the included trials, with inconsistent outcome measurement tools and short follow-up periods. Head-to-head trial data for these two drugs does not exist.